Biogen (BIIB) Cash & Current Investments (2009 - 2026)

Biogen's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 53.42% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (down 53.42% YoY), while the FY2025 annual figure was $3.8 billion, up 60.66% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $1.3 billion, down from $4.3 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $6.1 billion in Q2 2023, with the low at $1.0 billion in Q4 2023.
• The 5-year median for Cash & Current Investments is $3.3 billion (2022), against an average of $3.3 billion.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 78.69% in 2024, then surged 141.84% in 2025.
• Biogen's Cash & Current Investments stood at $4.9 billion in 2022, then tumbled by 78.54% to $1.0 billion in 2023, then soared by 126.21% to $2.4 billion in 2024, then surged by 60.66% to $3.8 billion in 2025, then plunged by 66.32% to $1.3 billion in 2026.
• Business Quant data shows BIIB's Cash & Current Investments at $1.3 billion in Q2 2026, $4.3 billion in Q1 2026, and $3.8 billion in Q4 2025.